Literature DB >> 11101876

BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.

J F Piskurich1, K I Lin, Y Lin, Y Wang, J P Ting, K Calame.   

Abstract

Class II transactivator (CIITA), a coactivator required for class II major histocompatibility complex (MHC) transcription, is expressed in B cells but extinguished in plasma cells. This report identifies B lymphocyte-induced maturation protein I (BLIMP-I), a transcriptional repressor that is capable of triggering plasma cell differentiation, as a developmentally regulated repressor of CIITA transcription. BLIMP-I represses the B cell-specific promoter of the human gene that encodes CIITA (MHC2TA) in a binding site-dependent manner. Decreased CIITA correlates with increased BLIMP-I during plasma cell differentiation in cultured cells. Ectopic expression of BLIMP-I represses endogenous mRNA for CIITA and the CIITA targets, class II MHC, invariant chain and H2-DM (the murine equivalent of HLA-DM) in primary splenic B cells as well as 18-81 pre-B cells. Thus, the BLIMP-I program of B cell differentiation includes loss of antigen presentation via extinction of CIITA expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101876     DOI: 10.1038/82788

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  78 in total

1.  PRDM1 is required for mantle cell lymphoma response to bortezomib.

Authors:  Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

Review 2.  Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases.

Authors:  Sun Jung Kim
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

3.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

Review 4.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

5.  Blimp-1/PRDM1 mediates transcriptional suppression of the NLR gene NLRP12/Monarch-1.

Authors:  Christopher A Lord; David Savitsky; Raquel Sitcheran; Kathryn Calame; Jo Rae Wright; Jenny Pan-Yun Ting; Kristi L Williams
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 6.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

7.  The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Authors:  Karin Tarte; Michel Jourdan; Jean Luc Veyrune; Ingolf Berberich; Geneviève Fiol; Nicole Redal; John Shaughnessy; Bernard Klein
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

Review 8.  Lessons for inductive germline determination.

Authors:  Riyad N H Seervai; Gary M Wessel
Journal:  Mol Reprod Dev       Date:  2013-02-28       Impact factor: 2.609

Review 9.  Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation.

Authors:  Shane Crotty; Robert J Johnston; Stephen P Schoenberger
Journal:  Nat Immunol       Date:  2010-01-19       Impact factor: 25.606

Review 10.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.